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Summary
Background The Thai phase 3 HIV vaccine trial RV 144 showed modest effi  cacy of a vaccine against HIV acquisition. 
Baseline variables of age, sex, marital status, and risk did not modify vaccine effi  cacy. We did a post-hoc analysis of the 
trial’s data to investigate behavioural risk and effi  cacy every 6 months after vaccination.
Methods RV 144 was a randomised, multicentre, double-blind, placebo-controlled effi  cacy trial testing the combination 
of the HIV vaccines ALVAC-HIV (vCP1521) and AIDSVAX B/E to prevent HIV infection or reduce setpoint viral load. 
Male and female volunteers aged 18–30 years were recruited from the community. In this post-hoc analysis of the 
modifi ed intention-to-treat population (16 395 participants), HIV risk behaviour was assessed with a self-administered 
questionnaire at the time of initial vaccination in the trial and every 6 months thereafter for 3 years. We classifi ed 
participants’ behaviour as low, medium, or high risk. Both the acquisition endpoint and the early viral-load endpoint 
were examined for interactions with risk status over time and temporal eff ects after vaccination. Multiple proportional 
hazards regression models with treatment and time-varying risk covariates were analysed.
Findings Risk of acquisition of HIV was low in each risk group, but 9187 (58·2%) participants reported higher-risk 
behaviour at least once during the study. Participants classifi ed as high or increasing risk at least once during follow-
up were compared with those who maintained low-risk or medium-risk behaviour as a time-varying covariate, and the 
interaction of risk status and acquisition effi  cacy was signifi cant (p=0·01), with greater benefi t in low-risk individuals. 
Vaccine effi  cacy seemed to peak early—cumulative vaccine effi  cacy was estimated to be 60·5% (95% CI 22–80) 
through the 12 months after initial vaccination—and declined quickly. Vaccination did not seem to aff ect viral load in 
either early or late infections.
Interpretation Future HIV vaccine trials should recognise potential interactions between challenge intensity and risk 
heterogeneity in both population and treatment eff ects. The regimen tested in the RV 144 phase 3 trial might benefi t 
from extended immunisation schedules.
Funding US Army Medical Research and Materiel Command and Division of AIDS, National Institute of Allergy and 
Infectious Disease, National Institutes of Health.
Introduction
The results of the phase 3 Thai HIV vaccine trial RV 1441 
suggest that a vaccine to prevent acquisition of HIV 
infection is possible.1 Although the effi  cacy was modest 
and insuffi  cient to warrant licensure, the study provided 
both insights and opportunities for future investigations 
into prevention of HIV acquisition. The investigators of 
the trial reported two salient, hypothesis-generating 
fi ndings: effi  cacy seemed greatest in participants at lower 
risk for HIV infection compared with the study-defi ned 
high-risk participants, and effi  cacy seemed maximum 
early after admin istration, but decreased with time.
By contrast with previous effi  cacy trials for HIV 
vaccines, the investigators of RV 144 enrolled mainly 
heterosexual people from a population with low 
prevalence of HIV.1 Most sexual encounters in RV 144 
were unlikely to be associated with risk of HIV 
transmission. Few incident cases in the study were from 
well defi ned high-risk groups such as sex workers, 
homosexual and bisexual men, or injecting drug users. 
The study was not designed to assess risk-stratifi ed 
effi  cacy rates and no signifi cant interaction between 
baseline risk and effi  cacy was noted,1 although estimated 
vaccine effi  cacy was greater than 40% in the low-risk 
groups at baseline, and less than 5% in high-risk 
participants. In other diseases, suffi  cient challenge doses 
can overwhelm vaccine-induced protective immune 
responses.2 The modest success noted in RV 144 could be 
because of low viral challenge encountered in the study 
population.
Results of non-human-primate challenge studies with 
high-dose, intravenous simian immunodefi ciency virus 
(SIV) and pathogenic simian HIV have suggested that 
protection from infection is not feasible, but a favourable 
modifi cation of early viral burden and clinical outcome is 
achievable.1 A notable outcome in RV 144 was the absence 
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of an eff ect on viral load in vaccine recipients.1 Most of 
these non-human-primate studies used intravenous or 
non-physiological, high-dose mucosal challenge doses of 
virus. Non-human-primate challenge studies3,4 with repeat, 
low-dose mucosal challenge with SIV after vaccination 
have shown protection from acquisition with no or variable 
eff ect on viral load or clinical outcome in animals with 
breakthrough infection. These fi ndings are consistent with 
the notion that available vaccines against SIV and simian 
HIV aff ord a reduction in acquisition risk in repeat, low-
dose mucosal challenge experiments that more closely 
model human transmucosal risk. Taken together, these 
fi ndings also suggest that the immune responses 
associated with protection from infection are mostly 
distinct from those needed for reduction of viraemia and 
improved clinical outcome, and are similar to the results of 
a summary of data from human trials of breakthrough 
infections with the ALVAC-protein boost regimen and an 
SIV non-human-primate challenge study.5–7
The RV 144 study was designed to acquire endpoints 
over 3·5 years after initial vaccination in more than 
16 000 volunteers with 90% statistical power to address 
the acquisition objective of 50% effi  cacy. This population 
size and extended follow-up was needed because of 
the ten-fold reduction in yearly HIV incidence in Thailand 
as a consequence of a vigorous public health campaign 
for prevention of HIV/AIDS.8,9 The trial was not designed 
to defi ne time-dependent eff ects. Nevertheless, the data 
suggest that effi  cacy fell during the extended observation 
period, although this fi nding was not signifi cant.1
We previously reported1 that baseline behavioural risk 
characteristics were balanced by treatment group and 
associated with diff erent placebo group transmission rates 
ranging from 0·227 per 100 person-years in the low-risk 
group to 0·364 per 100 person-years in the high-risk group 
(p=0·005, adjusted for treatment). However, estimates of 
vaccine effi  cacy were not signifi  cantly diff erent when 
compared by baseline behavioural risk covariate or any 
other parameter assessed, including sex, age, and baseline 
partnership status.1
We aimed to further explore, in a post-hoc analysis, the 
interaction of risk behaviour and effi  cacy during the full 
course of the study and examine time-dependent 
estimates of effi  cacy to guide the design of future effi  cacy 
trials for HIV vaccines.
Methods
Study design and participants
The main study methods and results including the 
screening, enrolment, and retention data by group 
have been published previously.1 Briefl y, RV 144 was 
a randomised, multicentre, double-blind, placebo-
controlled effi  cacy trial testing the combination of the 
HIV vaccines ALVAC-HIV (vCP1521) and AIDSVAX B/E 
to prevent HIV infection or reduce setpoint viral load. 
Male and female volunteers aged 18–30 years were 
recruited from the community irrespective of HIV risk 
through a separate screening protocol. Volunteers 
received a trial information briefi ng and gave written 
informed consent for participation in the screening 
protocol. HIV testing was done, and a follow-up visit at 
one of the eight clinical research sites was scheduled for 
2–3 weeks later.
Procedures
Volunteers returned for follow-up after the screening 
visit, were informed of their HIV test results and, if 
seronegative, written informed consent for participation 
in the trial was obtained and vaccinations begun. The 
protocol was reviewed and approved by the Ethical 
Committees of the Ministry of Public Health, the Royal 
Thai Army, Mahidol University, and the Human Subjects 
Research Review Board of the US Army Medical Research 
and Materiel Command.
Vaccinations were given over 24 weeks. The ALVAC-
HIV (vCP1521) or placebo prime was given in the left 
arm at weeks 0, 4, 12, and 24. Boosting with AIDSVAX 
B/E or placebo was given in the right arm at weeks 12 and 
24. The volunteers were followed up with HIV testing 
(with appropriate counselling before and after the test) 
every 6 months for 3 years. Plasma samples for HIV-1 
diagnostics were taken at 0 weeks and 24 weeks, and 
every 6 months during the follow-up phase. Research 
staff  provided education about reduction of risky 
behaviours during each vaccination and post-test 
counselling visit. The scheme for clinical trial conduct 
from screening to treatment and analysis allocation is 
published elsewhere.1
Assessment of HIV risk behaviour within the preceding 
6 months was done at baseline, 24 weeks, and each 
6 month follow-up visit with a self-administered 
questionnaire. Volunteers had to classify whether their 
everyday behaviour placed them at risk for HIV infection. 
The questionnaire then identifi ed specifi c risk behaviours 
for HIV acquisition. At each visit, participants were 
classifi ed as high risk if in the past 6 months they met 
one of the following criteria: reported that their behaviour 
placed them at risk for HIV; had shared needles when 
injecting drugs; had two or more sexual partners; had an 
HIV-positive sexual partner; had not used a condom 
during their last sexual contact (if this sexual contact had 
been within the past 6 months) with a sex worker, casual 
partner, same-sex partner, drug-injecting partner, or 
partner with several partners; had symptoms of a sexually 
transmitted infection; had used injecting drugs while in 
prison; or were employed at baseline as prostitutes or in 
the restaurants and bars where commercial sex 
transactions were commonly organised. Volunteers were 
deemed low risk if, in the previous 6 months, they 
perceived their behaviour did not place them at risk of 
HIV infection; had no or one sexual partner and no sex 
with sex workers, casual partners, same-sex partners, 
HIV-positive partners, drug-injecting partners, or 
partners with many partners; or had not been in prison 
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and reported no symptoms of sexually transmitted 
infections. The moderate risk category contained people 
with neither low nor high risk—eg, an individual with a 
single partner who was a sex worker, injecting drug user, 
same-sex partner, or casual partner, but had used 
condoms at the last sexual encounter. Individuals who 
did not answer an item on the risk questionnaire but 
were otherwise inconsistent with the high-risk profi le 
were classifi ed as moderate risk. The risk score categories 
were devised from baseline responses through use of 
combined-group infection results in a blinded fashion. 
The terms high, moderate, and low are relative to each 
other within this population and do not equate to typical 
defi nitions in high-risk cohorts.
Statistical analysis
Seven volunteers with prevalent infection at baseline 
were excluded, and the modifi ed intention-to-treat 
population was used for the analyses (16 395). To account 
for missing data because of people leaving the study 
early, we estimated the proportion of individuals with 
identifi ed risk characteristics with the product-limit 
survival method. Multiple proportional hazards 
regression models with treatment and time-varying risk 
covariates were analysed. Effi  cacy was higher in 
participants reporting low or medium risk at baseline 
than in those reporting high-risk behaviours at baseline. 
Taking all reported behaviours over time into 
consideration, participants with risk classifi ed as high or 
ever increasing by the time-varying covariate model were 
compared with those who had low or medium risk at 
entry and throughout the study. Vaccine effi  cacy was also 
assessed for maximum degree of risk reported during 
the study and risk degree reported in the study before 
seroconversion. Vaccine effi  cacy estimates from the 
Kaplan-Meier infection estimates were calculated every 
6 months. A non-parametric estimate of the relative 
hazard function and confi dence intervals were 
calculated.10 Descriptive statistics were generated and 
pointwise Wilcoxon tests of viral load were done. Two-
tailed p values are reported.
Role of the funding source
ALVAC-HIV (vCP1521) and ALVAC placebo were sup-
plied by the manufacturer, Sanofi  Pasteur. AIDSVAX and 
AIDSVAX placebo (VaxGen) were purchased by the 
Division of AIDS, National Institute of Allergy and 
Infectious Diseases, for the purpose of this trial. The US 
Army Medical Research and Materiel Command 
participated fully in data collection, determination of the 
analysis plan, and interpretation of data. The National 
Institute of Allergy and Infectious Diseases also par-
ticipated in analysis and data interpretation. The 
corresponding author had full access to all the data in the 
Baseline n (%) Ever n (%)
Everyday behaviour puts at risk 1620 (9·9%) 5613 (36·1%)
Needle sharing 133 (0·8%) 1250 (8·2%)
Two to four sex partners 1034 (6·3%) 2745 (17·5%)
More than four sex partners 205 (1·3%) 502 (3·2%)
No condom with casual partner 936 (5·7%) 2490 (15·9%)
No condom with sex-worker partner 62 (0·4%) 291 (1·9%)
No condom with same-sex partner 169 (1·0%) 429 (2·7%)
Condom with HIV-positive partner 227 (1·4%) 597 (3·8%)
No condom with HIV-positive partner 29 (0·2%) 143 (0·9%)
No condom with injecting drug user partner 18 (0·1%) 97 (0·6%)
No condom with many sex partners 258 (1·6%) 753 (4·8%)
Symptoms of sexually transmitted infection 479 (2·9%) 1613 (10·4%)
Injecting drug use while in prison 38 (0·2%) 181 (1·2%)
Occupation as sex worker* 86 (0·5%) ··
Works in  bar or restaurant where commercial sex transactions happen* 470 (2·9%) ··
Total number of people in at least one high-risk category 3945 (24·1%) 9187 (58·2%)
*Data collection at baseline only.
Table 1: Behavioural risk indicators for HIV infection at baseline and ever reported during the study   
Pr
op
or
tio
n 
of
 p
ar
tic
ip
an
ts
 (%
)
100
80
60
40
20
0
Week of visit
1821565226 1040 13078
Low risk
Medium risk
High risk
Placebo
Figure 1: Proportion of participants in each risk category over time
Participants were classifi ed as low, medium, or high risk on the basis of 
questionnaires administered at baseline and every six months thereafter for 
3·5 years.
Vaccine Placebo
Events (n) % infected SE Events (n) % infected SE Effi  cacy†
6 months 5 0·06% 0·028% 11 0·14% 0·042% 54·5%
12 months 12 0·15% 0·044% 30 0·38% 0·069% 59·9%
18 months 24 0·31% 0·063% 43 0·55% 0·083% 44·0%
24 months 32 0·41% 0·072% 50 0·64% 0·090% 35·7%
30 months 37 0·48% 0·078% 58 0·74% 0·097% 36·0%
36 months 45 0·58% 0·086% 65 0·84% 0·103% 30·4%
42 months 51 0·68% 0·096% 74 0·96% 0·111% 29·2%
*Vaccine effi  cacy=100×(1–% vaccine infection/% placebo infection). †Figures calculated before rounding.
Table 2: Cumulative vaccine effi  cacy* at 6 month intervals for the modifi ed intention-to-treat 
population determined from Kaplan-Meier infection rates
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study and had fi nal responsibility for the decision to 
submit for publication (each of the partners had the 
opportunity to comment).
Results
The proportion of participants classifi ed as low risk 
increased, and the numbers in the medium and high risk 
categories fell, during the fi rst 52 weeks of the study, and 
remained stable thereafter (fi gure 1). The distribution of 
risk for both overall category and individual risk items 
(data not shown) between treatment groups was 
balanced. Condom use was stable during the study for all 
partner types. The proportions of men and women in 
each risk category were similar (data not shown).
Participants could skip a question or report “I don’t know 
or I am not sure”, and these response rates fell as the study 
progressed. For example, 1218 of 16 373 (7·4%) respondents 
declined to answer the question about injecting drug use 
with needle sharing at study entry, but at the end of the 
study 303 of 14 794 (2·0%) declined to answer, with a small 
corresponding increase in reported rates both affi  rming 
and denying this behaviour over time. 105 (34·7%) of the 
participants who did not answer at the end of the trial also 
did not answer this question at baseline. Although the 
rates for individual and overall risk category did not 
systematically increase over time, the number of people 
who reported a high-risk factor at least once increased 
(table 1). Treatment groups did not diff er in risk categories 
at baseline or with time. At baseline, more people in the 
placebo group had seven of the 15 risk characteristics than 
in the intervention group, with a maximum excess risk 
disparity of 18 participants. More people in the vaccine 
group had the other eight risk characteristics. 5613 (36%) 
of participants reported a self-assessment of high-risk 
behaviour at least once during the study. Generally, all 
other specifi c risk items were far less common than self-
reporting of risk. Taken together, the proportion of 
participants self-classifi ed or assigned to the high-risk 
group on the basis of specifi c responses rose from 24·1% at 
entry to 58·2% when including all timepoints in the study 
(table 1). The number of HIV infections was similar in 
baseline high-risk (45) and low-risk participants (46) 
despite diff erent transmission rates because low-risk 
participants were more common at baseline. However, 
most infections (84) were identifi ed in participants who 
reported high-risk behav iour at baseline or during at least 
one subsequent visit. An additional 39 HIV infections 
were diagnosed in participants who initially reported low-
risk (n=28, 14 vaccine and 14 placebo) or medium-risk 
behaviour (11, fi ve vaccine and six placebo) and sub-
sequently reported at least one period of higher-risk 
behaviour. The interaction of risk with vaccine effi  cacy was 
signifi cant (p=0·01) between participants reporting high-
risk or increased-risk behaviour at least once and those 
reporting medium risk or low risk throughout the study on 
a time-varying basis. The vaccine effi  cacy estimate for 
participants who maintained low or medium risk from 
entry throughout the entire study was 68% (95% CI 34–84, 
p=0·002). We noted little vaccine eff ect for the high-risk 
group (vaccine effi  cacy 5%, 95% CI –46 to 38).
Although we identifi ed an interaction with risk, the 
most important risk behaviours for HIV transmission 
contributed little to the fi ndings of RV 144. For example, 
although injecting drug use with needle sharing was 
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Figure 3: Viral load for vaccine and placebo groups
Viral loads measured after infection are plotted for vaccine and placebo groups restricted to those who acquired 
HIV within 600 days of fi rst vaccination (A) or after 600 days (B). 0 weeks is time of diagnosis of HIV infection. 
Error bars show the SE.
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Figure 2: Vaccine effi  cacy point estimates over time
Vaccine effi  cacy rates are given over time (red line) with 95% pointwise CIs (green line) and 95% simultaneous CIs 
(blue line).
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commonly reported (n=1250 [8·2%]), only fi ve (two vaccine 
and three placebo) HIV infections were reported in this 
group. In men reporting sex with men, only 16 HIV 
infections were noted (eight vaccine and eight placebo).
Vaccine effi  cacy fell at each interval (table 2), with 
endpoint ascertainment after 12 months, but the 
interaction of time from fi rst immunisation and 
outcome was not signifi cant (p=0·36).1 Nevertheless, 
the early timepoint effi  cacy estimates reported after 
completion of the vaccine series were substantially 
greater than those at conclusion of the study—vaccine 
effi  cacy was 54·5% at 6 months and 59·9% at 12 months 
compared with 29·2% at 42 months. The transmission 
rate for the placebo group varied modestly from 
0·38 per 100 person years in year one to 0·26 per 
100 person years in the fi nal year of the investigation. 
In proportional hazards models that specifi ed the log 
hazard ratio (vaccine vs placebo) as various smooth 
functions of time (linear, log-linear, quadratic, and 
piece-wise cubic polynomials in three or four 
segments), results were generally consistent with 
effi  cacy, which was most clearly evident early and 
declined from the second year of follow-up to the end of 
the study (data not shown). A non-parametric analysis 
gave a similar result, with early instantaneous hazards 
effi  cacy falling to 0 by 18 months (fi gure 2).
In an additional post-hoc analysis we assessed the 
relation between timing of infection and viral load. The 
viral-load endpoint was the average of three samples 
acquired during the fi rst 6 weeks after serodiagnosis of 
HIV infection. This endpoint was assessed for acqui-
sition events arising within 600 days of initial vaccination 
(a period with high effi  cacy rate estimates) separately 
from events reported after this period when effi  cacy fell. 
We detected no diff erence in viral load at any timepoint 
after infection or in mean early viral load (the co-primary 
endpoint) between the vaccine and placebo groups when 
segregated by proximity to vaccination (fi gure 3). The 
eff ect of vaccine on viral load did not diff er either by 
baseline risk group or in participants classifi ed as high 
risk or increased compared with baseline risk.
Discussion
Vaccine effi  cacy in the RV 144 trial was unrelated to 
baseline variables including risk assessment (panel). The 
risk assessment variable is signifi cant with respect to 
out come when considered over the course of the study. 
Further, the effi  cacy estimate was highest in the fi rst 
6 months after completion of vaccination and fell rapidly.
Risk of infection is a complex, compound estimate of 
several eff ects but can be simply assessed.11 Aggregate 
risk of infection is a function of donor challenge (eg, risk 
that source is HIV positive, viral load, presence of 
cofactors including sexually transmitted infections and 
bleeding), recipient susceptibility (eg, genetically defi ned 
host characteristics, route of infection, presence of 
cofactors), and frequency of exposure.
For example, HIV infection in individuals with 
deletions of CCR5 are uncommon, but if they are exposed 
frequently the cumulative probability of encountering 
someone infected with the X4 virus mitigates the 
protective benefi t of this element of genetic resistance.12 
Furthermore, data from human vaccine and challenge 
experiments provide convincing evidence that induction 
of protective immunity can be overcome with a single 
suffi  ciently large challenge.2 In non-human primate 
studies, to reproducibly and effi  ciently overcome 
infectious challenge doses and routes seems to need an 
immune response that is unachievable for the current 
generation of vaccines. In Vax003, a trial13 that used 
AIDSVAX B/E in Thai injecting drug users, the absence 
of effi  cacy might have been because of the stringency of 
intravenous challenge when compared with the 
intravaginal and intrarectal routes. This stringency could 
be because of the circumvention of mucosal barriers and 
related genetic bottlenecks or the avoidance of vaccine-
associated immune responses at mucosal sites. Several 
lines of evidence14–16 suggest that the challenge experienced 
by injecting drug users is higher in magnitude and 
genetic diversity than both that faced by non-injecting-
drug users and that faced by people infected by a non-
intravenous route. Possibly, human vaccines tested in 
effi  cacy trials thus far provided only modest time-sensitive 
reduction in host susceptibility that was un done by the 
aggregate transmission challenge intensity.
Vaccine-induced immune responses can reasonably be 
assumed to be independent of volunteer risk status. The 
absence of effi  cacy in high-risk participants in RV 144 
could be because of either the higher challenge per 
exposure or more frequent exposure, or both, compared 
with low-risk participants, with participants infected if the 
threshold exposure occurred when immune responses 
were inadequate to contain the virus (fi gure 4). By contrast, 
the population maintaining low risk throughout the study 
Panel: Research in context
Systematic review
We systematically searched PubMed  with the search terms 
“vaccine effi  cacy”, “HIV vaccine trial”, and “HIV vaccine clinical 
study” for HIV vaccine effi  cacy trials published in English to 
identify all randomised controlled trials with behavioural data 
and a positive outcome. We did not identify any previous 
studies of HIV vaccines showing effi  cacy. There was no 
restriction on dates of publication.
Interpretation
The effi  cacy and benefi t noted in RV 144, which enrolled a 
population with a low incidence of HIV infection, fell quickly 
after 12 months and accrued mainly to participants who did 
not report or perceive themselves to show traditional HIV risk 
behaviours. Future studies will need to account for participant 
risk and temporal eff ects. This pox–protein prime boost 
regimen might show improved effi  cacy with extended boosts.
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(in whom effi  cacy was noted) probably have fewer and 
possibly less challenging exposures than the high-risk 
group (fi gure 4). Frequency and route of exposure, and 
cofactors such as sexually transmitted infections are the 
basis for consideration of the diff erent degrees of 
challenge intensity17,18 and, correspondingly, the diff erent 
magnitudes of vaccine-induced immunity needed to 
achieve protection against HIV infection. Furthermore, 
we can deduce that vaccine-induced responses must be 
both high in magnitude and sustained to achieve similar 
effi  cacy in high-intensity challenge populations. Figure 4 
shows a modest, time-limited protective immune 
response (as reported in RV 144) and suggests an 
additional boost or other augmentation of immune 
response would improve effi  cacy for all risk categories.
A second possibility assumes a more complex model in 
which diff erent immune responses protect against high-
risk and low-risk challenges (eg, responses might occur 
in diff erent mucosal compartments); the diff er ential 
decay of these protective responses could explain the early 
protective eff ect seen in RV 144. Correlation of immune 
responses induced by the ALVAC-HIV and AIDSVAX 
B/E regimen to the temporal pattern of protection will be 
crucial to guide future vaccine development.
Many researchers think that most HIV vaccines under 
development will not prevent acquisition of HIV infection 
because they do not stimulate production of neutralising 
antibodies.19,20 A more realistic goal for vaccine 
development is thought to be induction of T-cell immunity 
to reduce early viral load and slow disease progression, as 
has been noted in high-dose challenge studies in non-
human primates21–23 and inferred from studies of elite 
controllers and long-term non-pro gressors infected with 
HIV.24 Despite the apparent absence of neutralising 
antibodies against primary HIV isolates or broadly 
neutralising activity, the ALVAC prime and AIDSVAX 
boost reduced acquisition by 31·2% at 42 months.1 This 
regimen did not reduce early viral load even when 
examined in the period shortly after vaccination when 
anti-acquisition effi  cacy seems highest. This result is 
consistent with the notion that effi  cacy against acquisition 
requires a diff erent set of immune eff ectors from those 
needed for reduction in viral load and altered prognosis.
Haynes and colleagues25 reported that IgG against a 
conformational glycoprotein 120 V1V2 epitope was 
inversely correlated with infection in RV 144. These 
data prompted Barouch and co-workers7 to look for 
anti-V2 responses in non-human primates vaccinated 
with adenovirus type 26 and modifi ed-vaccinia-ankara 
vectored SIV inserts; anti-(SIV)V2 responses were 
inversely correlated with infection risk. These fi ndings 
raise additional hypotheses related to the potential decay 
of immune responses in the plasma or mucosal 
compartments.
The value of a vaccine aff ording modest protection 
in low-challenge-intensity settings as a public health 
intervention is questionable, but some researchers argue 
that such a vaccine might be cost eff ective in the Thai 
setting.26,27 Nevertheless, the value of protection against 
human-to-human transmission of HIV cannot be 
underestimated. Further elucidation of the nature of 
protection aff orded in more permissive settings could 
allow optimisation of vaccine strategies to achieve 
qualitatively and quantitatively superior vaccines with 
expanded effi  cacy. Our data should be carefully considered 
in terms of the inherent risks of a post-hoc analysis and 
are intended to identify subjects deserving further 
consideration in future effi  cacy trials. The questions 
raised by the data from RV 144 are probably more 
important to the future of HIV vaccine development than 
are the primary fi ndings of the trial. Among these issues, 
the temporal nature of protection and the interaction with 
risk should be studied in more detail in HIV vaccine trials.
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